MDXH Market Analysis

Wall Street coverage

third-party context

Wall Street coverage

$2.80median target· current $0.42 (+569.9%)6 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratioForward 27.70
EPS (TTM)$-0.650.0% YoY
Profit margin-29.9%HEALTHCARE
Market cap$21.5MMicro cap

Valuation

Forward P/E
27.70
PEG ratio
P/B
23.64
P/S (TTM)
0.19
EV/EBITDA
17.57

Profitability & growth

ROE (TTM)
-2440.0%
Operating margin
-26.7%
Revenue growth YoY
12.7%
Dividend yield
Beta
-503341.44
Last earnings
May 13, 2026 · Estimate $-0.15 · Reported $-0.17
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About MDxHealth SA ADR

Company profile

MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, exemplifies the company's commitment to clinical efficacy and personalized medicine, establishing a strong foothold in a rapidly growing market. As the demand for targeted cancer therapies increases, MDxHealth is poised to expand its diagnostic offerings, effectively addressing critical unmet needs in oncology and improving patient outcomes. With its innovative solutions and…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
CAP BUSINESS CENTER, HERSTAL, BELGIUM
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$21.5M
Shares outstanding$51.4M
52W high$5.33
52W low$0.40

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer